Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15063164 | 1.00 | CHRM3 (0.46) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL15063220 | 0.85 | CHRM3 (0.48) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL15063218 | 0.85 | CHRM3 (0.48) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL15063137 | 0.84 | CHRM3 (0.51) | CHRM3CHRM2CHRM1KDM4EALDH1A1 | |
| SCHEMBL15063136 | 0.84 | CHRM3 (0.51) | CHRM3CHRM2CHRM1KDM4EALDH1A1 | |
| SCHEMBL15063168 | 0.78 | CHRM3 (0.58) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL15063259 | 0.78 | CHRM3 (0.58) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL15063171 | 0.78 | CHRM3 (0.58) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL15063257 | 0.78 | CHRM3 (0.58) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL15063234 | 0.77 | CHRM3 (0.59) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797910-B1 | QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMA SPA (IT) | 2015-09-16 | — | — | EP | disclosed |
| EP-2797910-A1 | QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF | Chiesi Farmaceutici S.p.A. (IT) | 2014-11-05 | — | — | EP | disclosed |
| US-8748613-B2 | Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-10 | — | — | US | disclosed |
| US-20130172302-A1 | QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-07-04 | — | — | US | disclosed |
| WO-2013098145-A1 | QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172302-A1 | QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885CHRM2 2/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.